Catalogue Number: AB02187-7.4-ABA
| Manufacturer: | Vector Laboratories, Inc (ABA) |
| Type: | Recombinant Monoclonal |
| Shipping Condition: | Blue Ice |
| Unit(s): | 200 ug |
| Host name: | Rat |
| Clone: | RMT1-10 |
| Isotype: | IgG2a |
| Immunogen: | The original rat IgG2a version of this antibody was raised by immunizing SD rats with full-length Tim-1-Ig that contained both IgV and mucin domains of Tim-1. Lymph node cells were then fused with P3U1 myeloma cells and cloned creating hybridomas. |
| Application: | ELISA, FC, IF, Inh |
HAVCR1
Q5QNS5
171283
Purified
Recombinant Monoclonal
Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
CD365; HAVcr-1; HAVCR1; Hepatitis A virus cellular receptor 1 homolog; Kidney injury molecule 1; KIM-1; T cell immunoglobulin and mucin domain-containing protein 1; T cell membrane protein 1; T-cell immunoglobulin and mucin domain containing 1; T-cell immunoglobulin mucin receptor 1; TIM-1; TIM1; TIMD-1
This anti-Tim-1 antibody inhibits the generation of antigen-specific T cells, production of IFN-γ and IL-17, and development of autoimmunity, and it caused a strong Th2 response (Xiao et al., 2007; pmid: 17606630). RMT1-10 gives then rise to opposite effects than those brought about by another anti-Tim1 clone - 3B3 (Ab01032) which achtivates T-cells. The use of RMT1-10 demonstrated that binding Tim-1 can not only lead to activation of T-cells (as it had been known before) but that it can also cause the aforementioned inhibition (Xiao et al., 2007; pmid: 17606630). Consequently, the opposite antibodies RMT1-10 and 3B3 (Ab01032) can be utilized together to study various aspects of Tim-1 costimulation and its consequences. This antibody was used in multiple flow cytometry (FC/FACS) experimetns, such as identifying Tim-1-expressing EL-4 cells to determine the antibody's epitope (Xiao et al., 2007; pmid: 17606630). Furthermore, Tim-1 activation was suggested as an important factor in certain pathologies, and thus this inhibitory antibody can be useful for research on the potential treatment options. For instance, RMT1-10 was utilized in a research model of glomerular disease. It was demonstrated that crescentic glomerulonephritis, proliferative injury, and leukocyte accumulation were attenuated following treatment with RMT1-10, but interstitial foxp3+ cell accumulation and interleukin-10 mRNA were increased. Apoptosis and T-cell proliferation as well as Th1 and Th17 responses decreased both in the whole model organism as well as in kidney (Nozaki et al., 2012; pmid: 22205357). Another study showed that RMT1-10 attenuates atherosclerosis by expanding IgM-producing B1a cells (Hosseini et al, 2018; pmid: 29936416). Finally, another group demonstrated that this clone promotes the survival corneal allografts in mice what is associated with the increase in T regulatory cells (Tan et al., 2014; pmid: 24613782).